Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity

Pinkerton, CR, McDermott, B, Philip, T, Biron, P, Ardiet, C, Vandenberg, H and Brunatmentigny, M (1988) Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity. Cancer Chemotherapy and Pharmacology, 22 3: 271-274. doi:10.1007/BF00273423


Author Pinkerton, CR
McDermott, B
Philip, T
Biron, P
Ardiet, C
Vandenberg, H
Brunatmentigny, M
Title Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity
Journal name Cancer Chemotherapy and Pharmacology   Check publisher's open access policy
ISSN 0344-5704
Publication date 1988-01-01
Year available 1988
Sub-type Article (original research)
DOI 10.1007/BF00273423
Open Access Status Not yet assessed
Volume 22
Issue 3
Start page 271
End page 274
Total pages 4
Publisher Springer-Verlag
Language eng
Subject 3004 Pharmacology
2730 Oncology
1306 Cancer Research
Abstract A 5-day continuous infusion of vincristine (VCR; total dose 4 mg/m2) has been given as part of a high-dose chemoradiotherapy regimen with bone marrow transplantation. Evidence of neurotoxicity, such as weakness, paraesthesia and intestinal hypomotility, was evaluated prospectively in nine patients. Five patients had advanced neuroblastoma and four, relapsed sarcomas, and all had responded to initial conventional-dose therapy. VCR was combined with high-dose melphalan (180 mg/m2) and fractionated total-body irradiation. Plasma concentrations of VCR were measured by radioimmunoassay during and up to 24 h after the infusion. Serum and urine electrolytes and liver function tests were measured during VCR treatment and at regular intervals thereafter. VCR concentration at 1 h ranged from 1.8 to 10.9 (median 6.6) ng/ml, and a steady state was achieved by 13-30 h (median 16 h). Levels above 1 ng/ml were maintained throughout the 5-day period with a mean steady-state concentration of 1.7 ng/ml (range 1.3-2.15). After cessation of the infusion, serum concentrations fell to below 0.25 ng/ml within 24 h. Abdominal pain occurred in one patient, but neither constipation nor ileus was seen. In two patients severe muscle pain occurred in the lower limbs towards the end of the infusion. Significant electrolyte problems did not occur and, in particular, there was no evidence of inappropriate ADH secretion. Transient increases in liver enzymes were common but bilirubin was not elevated during the period of monitoring. This regimen allows a two-fold escalation in the dose of VCR to be administered, producing sustained high serum drug levels without major toxicity.
Keyword Oncology
Pharmacology & Pharmacy
Oncology
Pharmacology & Pharmacy
ONCOLOGY
PHARMACOLOGY & PHARMACY
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 20 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 20 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:16:58 EST by System User